No problem......thanks for asking for further deeper perspective!! Again, here it is.
The second issue I want to focus on just for a second is the improvement in the balance sheet. If you look deeply -- I mean deeply -- into the 10-K, you'll see that the number of preferred shares outstanding has decreased. And that has continued even past the March 31 deadline for the fiscal 2012.
And what that means, I mean, there are corporate reasons for that that matters, but the most important reason for shareholders is that we will no longer be issuing dividends to those preferred shareholders, which means less dilution for common shareholders. We think that's a good thing.
So the other thing I would like to do is sort of sum up what our goals are for fiscal 2013. We continue to want to drive the Company towards cash flow positive, excluding the additional expense for bioequivalent studies on bioequivalence products.
Just like previously, that requires us to get to an annual run rate of a little over $4 million, and Carter can correct me if I'm wrong about that, but I think that's correct. We are getting there; we're definitely getting there. With a little help from the FDA, we will get there in fiscal 2013.
News 
Market Data 
Discover 
AI
